Medindia

X

Abaxis to Report Fourth Quarter and Fiscal Year 2010 Financial Results Thursday, April 29, 2010

Thursday, April 22, 2010 General News J E 4
Advertisement


UNION CITY, Calif., April 22 Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2010, ended March 31, 2010. The call will be at 4:15 p.m. ET on Thursday, April 29, 2010.

Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at www.abaxis.com. A replay of the call is available by visiting www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 440020, through May 3, 2010.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

Contact: Clint Severson Lytham Partners, LLC Chief Executive Officer Joe Dorame, Joe Diaz & Robert Blum Abaxis, Inc. 602-889-9700 510-675-6500

SOURCE Abaxis, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Actelion Pharmaceuticals Announces Commercial Avai...
S
Clarient to Announce 2010 First Quarter Financial ...